The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes-Reference-Cited by-同舟云学术

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes

Published:2019-03-15 Issue:6 Volume:21 Page:1311-1321
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

He Yan‐Ling¹^ORCID,Haynes William¹²,Meyers Charles D.¹³,Amer Ahmed⁴,Zhang Yiming⁵,Mahling Ping⁶,Mendonza Anisha E.¹,Ma Shenglin¹,Chutkow William⁷,Bachman Eric¹⁸

Affiliation:

1. Translational Medicine, Novartis Institutes for BioMedical Research Cambridge Massachusetts

2. Novo Nordisk Research Centre Oxford UK

3. Chief Medical Office, Anji Pharmaceuticals Cambridge Massachusetts

4. CMO and Patient Safety, Novartis Pharmaceuticals Corporation East Hanover New Jersey

5. Early Development Biostatistics, Biostatistics and Pharmacometrics, Novartis Institutes for BioMedical Research East Hanover New Jersey

6. DEV B&SS, CM/Global Health, Novartis Institutes for BioMedical Research Cambridge Massachusetts

7. Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research Cambridge Massachussets

8. Vertex Pharmaceuticals Boston Massachusetts

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13654

Reference49 articles.

1. The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors

2. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

3. WHOObesity and overweight factsheet.2018.

4. Mechanisms, Pathophysiology, and Management of Obesity

5. Global obesity: trends, risk factors and policy implications

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes;ESC Heart Failure;2024-09-10

2. Efficacy of powder of ginsengporia and atractylodis macrocephalae combined with aerobic exercise in the treatment of obese T2DM: A randomized controlled clinical trial;Electronic Journal of Biotechnology;2024-09

3. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies;Chinese Journal of Natural Medicines;2024-08

4. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?;Metabolism;2024-08

5. The Efficacy of Pharmacotherapy in the Treatment of Obesity in Patients With Type 2 Diabetes: A Systematic Review;Cureus;2024-07-24